Aridis Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Aridis Pharmaceuticals has been growing earnings at an average annual rate of 96.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 680.4% per year.
Key information
96.5%
Earnings growth rate
98.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 680.4% |
| Return on equity | n/a |
| Net Margin | -5.1% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%
Sep 26Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M
Aug 16Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?
Feb 17
Aridis Pharmaceuticals EPS misses by $0.02
Nov 20Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow
Oct 31Revenue & Expenses Breakdown
How Aridis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 22 | -1 | 6 | 0 |
| 30 Jun 23 | 22 | -9 | 6 | 0 |
| 31 Mar 23 | 3 | -29 | 7 | 0 |
| 31 Dec 22 | 3 | -30 | 7 | 0 |
| 30 Sep 22 | 3 | -33 | 8 | 0 |
| 30 Jun 22 | 3 | -49 | 8 | 0 |
| 31 Mar 22 | 3 | -46 | 8 | 0 |
| 31 Dec 21 | 2 | -46 | 7 | 0 |
| 30 Sep 21 | 1 | -43 | 7 | 0 |
| 30 Jun 21 | 0 | -25 | 7 | 0 |
| 31 Mar 21 | 1 | -24 | 7 | 0 |
| 31 Dec 20 | 1 | -22 | 6 | 0 |
| 30 Sep 20 | 1 | -22 | 6 | 0 |
| 30 Jun 20 | 1 | -24 | 6 | 0 |
| 31 Mar 20 | 0 | -28 | 6 | 0 |
| 31 Dec 19 | 1 | -30 | 6 | 0 |
| 30 Sep 19 | 2 | -29 | 6 | 0 |
| 30 Jun 19 | 3 | -30 | 5 | 0 |
| 31 Mar 19 | 3 | -23 | 4 | 0 |
| 31 Dec 18 | 3 | -23 | 4 | 0 |
| 30 Sep 18 | 2 | -24 | 3 | 0 |
| 30 Jun 18 | 1 | -22 | 3 | 0 |
| 31 Mar 18 | 1 | -27 | 3 | 0 |
| 31 Dec 17 | 1 | -27 | 3 | 0 |
| 30 Sep 17 | 0 | -26 | 3 | 0 |
| 31 Dec 16 | 2 | -9 | 2 | 0 |
| 31 Dec 15 | 3 | -8 | 3 | 0 |
Quality Earnings: ARDS is currently unprofitable.
Growing Profit Margin: ARDS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ARDS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ARDS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARDS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ARDS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.